Thoracic radiation therapy in limited stage small-cell lung cancer: Timing is everything...isn't it?

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 3815-3816

  Perry, Michael C ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; COBALT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CAV PROTOCOL; VP P PROTOCOL; VP-P PROTOCOL;

ADJUVANT THERAPY; BONE MARROW BIOPSY; BRAIN METASTASIS; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; ESOPHAGITIS; HEAD AND NECK CANCER; HUMAN; LUNG FUNCTION TEST; LUNG SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; MULTICENTER STUDY; NOTE; PATHOLOGY; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA; SURVIVAL; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE FRACTIONATION; DOXORUBICIN; ETOPOSIDE; HUMANS; LONDON; LUNG NEOPLASMS; META-ANALYSIS; MULTICENTER STUDIES; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33748459451     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.2827     Document Type: Editorial

References (10)

1. Pignon J-P, Arrigada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
2. Arriagada R, Le Chevalier T, Borie F, et al: Prophylactic cranial irradiation for patients with small cell lung cancer in remission. J Natl Cancer Inst 87:183-190, 1995
3. Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
4. Spiro SG, James LE, Rudd RM, et al: Early compared with late radiotherapy in combined-modality treatment for limited-disease small-cell lung cancer: A London Lung Cancer Group multicenter randomized clinical trial. J Clin Oncol 24:3823-3830, 2006
5. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993
6. Perry MC, Herndon JE II, Eaton WL, et al: Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083. J Clin Oncol 16:2466-2467, 1998
7. Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837-4845, 2004
8. De Ruysscher D, Pijls-Johannesma M, Bentzen S, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small cell lung cancer. J Clin Oncol 24:1057-1063, 2006
9. Brade AM, Tannock IF: Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause for treatment failure? J Clin Oncol 24:1020-1022, 2006
10. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002